EKR Therapeutics news from FierceBiotech
NewsC&L: Bethune tapped as interim Zila CEO
Zila Chairman David Bethune is taking on the role of acting CEO. That post has been empty since last June, when Doug Burkett left the job. Barr Pharmaceuticals announced the following promotions: Read more...
Genmab buys antibody plant in $240M deal
PDL BioPharma has inked a deal to sell its U.S. antibody manufacturing plant to Denmark's Genmab for $240 million. The deal--which will enable Genmab to transition three Read more...
| Press ReleasesPRESS RELEASE: EKR Therapeutics Achieves Key Growth Milestone with Acquisition of Rights from Pacira Pharmaceuticals to DepoDurEKR Therapeutics Achieves Key Growth Milestone with the Acquisition of Rights from Pacira Pharmaceuticals to DepoDur, a Novel Extended-Release Opioid Analgesic for Post Operative Pain CEDAR KNOLLS, Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets